tbuckley/cabot-search huggingface dataset:
Abstract MP212: Integrated Genomics Analysis Identifies Recessive Ciliopathy Mutations In Primary Endocardial Fibroelastosis: A Rare Neonatal Cardiomyopathy
Authors: Zubin Mehta, Yan Zhao, Kang Xuedong, Juan C Alejos, Nancy Halnon, Stanley F Nelson, Marlin Touma
Journal: Circulation Research (2021)

Background: Among neonatal cardiomyopathies, primary endocardial fibroelastosis (pEFE) remains a mysterious disease of the endomyocardium, affecting 1/5000 live births and accounting for 25% of the entire pediatric dilated cardiomyopathy (DCM) population with a devastating course and grave prognosis. Objective: We aimed to investigate potential genetic contributions to pEFE etiology. Methods: We performed integrative genomic analysis in 8 infants with confirmed pathological diagnosis of pEFE using whole exome sequencing (WES), RNA-seq and functional genomics studies. Patient-derived fibroblasts, neonatal rat ventricular myocytes and neonatal rat cardiac fibroblasts were used for cellular assays. Real-time cell migration and proliferation analyses were performed using xCELLigence technology. Results: Whole exome sequencing detected novel and deleterious de novo single nucleotide variants, or inherited homozygous rare variants in 11 cilia-related genes in seven out of the eight affected probands. In particular, a novel homozygous variant [c.1938delA] in ALMS1 was identified in a female proband, pEFE4. This variant resulted in a frameshift introducing a premature stop codon and complete absence of the ALMS1 protein in the proband fibroblasts and explanted heart. Loss of function mutations of ALMS1 have been implicated in Alstrom syndrome [OMIM 203800], a rare recessive ciliopathy. RNA-sequencing of the proband’s dermal fibroblasts revealed significantly dysregulated cellular signaling and function, including the induction of epithelial mesenchymal transition (EMT), potentially mediated by TGFβ signaling activation. The proband fibroblasts exhibited enhanced migration activity. Herein, we present the unique pathological features of pEFE compared to DCM and utilize integrated WES with RNA-seq analysis to elucidate the molecular mechanisms by which the novel causal ALMS1 variant contributes to the unique pathology of pEFE in a female infant with Alstrom syndrome. Conclusions: Our report provides insights into pEFE etiology and suggests, for the first time to our knowledge, ciliopathy as a potential underlying mechanism for this poorly understood and incurable form of neonatal cardiomyopathy.
Tumors of the Parathyroid Glands.
Journal: Annals of Internal Medicine (1979)

This slim fascicle is an excellent summary and atlas of its subject, as would be expected by those who knew the first edition by Castleman alone, now long out of print.In addition to the valuable practical exposition there are interesting sections on the history of hyperpara- thyroidism and the possible functional cycle of parathyroid cells-the latter somewhat speculative.One may disagree with the authors on the emphasis on mitotic activity as the single most valuable point in diagnosing carcinoma, consider their restriction on the use of the term clear cell unnecessary, the description of colloid somewhat scrappy, and the treat- ment of tertiary hyperparathyroidism perfunctory.However, it is a book that all concerned with the practical manage- ment of hyperparathyroidism-physicians and surgeons as well as pathologistswill find invaluable.
The need for an increased number of consultant physicians with specialist training in gastroenterology.
Journal: Gut (1984)

Abstract Medical gastroenterology has developed with great rapidity in the last decade with the introduction of new investigative and therapeutic techniques. Nearly every district general hospital now has on its staff a consultant physician with this special interest, and yet there is still a need for a further expansion in the number of such consultants. This memorandum explains why and where further consultants are needed.
AMA Insights
Journal: JAMA (1987)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
HyperCVAD for VAD‐resistant multiple myeloma
Authors: Meletios A. Dimopoulos, Donna Weber, Hagop Kantarjian, Kay B. Delasalle, Raymond Alexanian
Journal: American Journal of Hematology (1996)

More effective and safer regimens are needed for patients who have advanced multiple myeloma resistant to or relapsing despite prior treatment with alkylating agents and VAD. We treated 58 such patients using the combination of twice daily cyclophosphamide (total dose 1.8 g/m2) and VAD (hyperCVAD). Treatment was given to outpatients followed by G-CSF at 5 μg/kg/d until granulocyte recovery. Twenty-three patients responded (40%), with a median duration of granulocyte depression to less than 500/μl of 4 days and a mortality rate of 2%. The median survival time for all patients was 15 months, and the median remission time of responding patients was 8 months. Patients who had low LDH, low B2M, or primary resistant disease lived significantly longer than patients without these features. The combination of fractionated cyclophosphamide and VAD provided an effective and safe rescue treatment for many patients who had advanced myeloma resistant to standard therapies. © 1996 Wiley-Liss, Inc.
Pulmonary varix.
Authors: J C Arnett, R M Patton
Journal: Thorax (1976)

<b>Objective:</b> To investigate the relationship between temporal discrimination threshold (TDT) and "off" period gait freezing (OGF) in patients with fluctuating Parkinson disease (PD). <b>Methods:</b> TDT values were measured at the dorsum of the toes in 11 control subjects and 22 patients with PD with a wearing-off phenomenon (16 patients with OGF and 6 patients without OGF). <b>Results:</b> During the l-dopa "off" period, TDT values increased abnormally in both patient groups but were significantly higher in patients with OGF than in those without OGF. A positive correlation was found between the severity of OGF and TDT values measured by different point stimulation. In patients with OGF, a single dose of l-dopa treatment normalized TDT values and ameliorated OGF. <b>Conclusions:</b> Dopa-responsive abnormal discriminative sensory processing may be a possible cause of "off" period gait freezing observed in patients with fluctuating Parkinson disease.
On Diabetes and its Connection with Heart Disease
Authors: J. Mayer
Journal: BMJ (1888)

THEB BAiTiII MEDICAL JOURINAL.949 abnormal tissue-waste, and consequlently increases the weight of the body; it causes neither narcosis nor constipation in' doses whicli would be positively (langerouis if given in other diseases.Still more efficacious is 'morphine, in doses of from 1 to 3 grains daily.The beneficial effect of these drugs, however, does tot last very long; after three or four months they lose their effect, and there is, moreover, the risk of the opium-habit becoming con- firmed.They should, therefore, be taken only at long intervals, and under strict medical supervision.Salicylic acid, phenol, and salicylate of sodium, are far less useful.In conclusion, I venture to lay downa the following propositions, as summing up the results of my studies and observations: 1.We are still in total ignorance as to the etiology of diabetes mellitus.2. The quantity of sugar found in the urine is of no signifi- cance at all in judging of the severity and danger of any particular case of diabetes.3. The smallest traces of sugar, found only by most eareful chemical examination of the urine, are of considerable importance in a great many cases, so that they cannot be left out of account in trying to arrive at a correct diagnosis and prognosis.4. The dietetic treatment must be adapted to the special re- quirements of eachi case, as there are cases in which, without regard to the amount of sugar excreted, complete abstention from starchy matters is not only useless, but directly injurious.-5.According to the present knowledge, strict antidiabetic diet, combined with the use of the mineral waters of Carlsbad, is the best method of treating diabetes mellitus.
Retraction Notice to: The YY1-HOTAIR-MMP2 Signaling Axis Controls Trophoblast Invasion at the Maternal-Fetal Interface
Authors: Yan Zhang, Feng Jin, Xiao-Cui Li, Fu-Jin Shen, Xiao-Ling Ma, Fan Wu, Si-Ming Zhang, Wei-Hong Zeng, Xiao-Rui Liu, Jian-Xia Fan, Yi Lin, Fu-Ju Tian
Journal: Molecular Therapy (2022)

(Molecular Therapy 25, 2394–2403; October 2017) This article has been retracted at the request of the editors. After investigating concerns of image duplication raised by a reader, evidence for image duplication in identical or altered fashion in Figures 2D, 3H, and 5C was identified. This reuse (and in part misrepresentation) of data without appropriate attribution represents a severe abuse of the scientific publishing system. RETRACTED: The YY1-HOTAIR-MMP2 Signaling Axis Controls Trophoblast Invasion at the Maternal-Fetal InterfaceZhang et al.Molecular TherapyJuly 4, 2017In BriefThis article has been retracted: please see Elsevier Policy on Article Withdrawal ( http://www.elsevier.com/locate/withdrawalpolicy ). Full-Text PDF Open Archive
Formulation of pH-responsive PEGylated nanoparticles with high drug loading capacity and programmable drug release for enhanced antibacterial activity
Authors: Dawei Li, Guoke Tang, Hui Yao, Yuqi Zhu, Changgui Shi, Qiang Fu, Fei Yang, Xing Wang
Journal: Bioactive Materials (2022)

In the current global crisis of antibiotic resistance, delivery systems are emerging to combat resistant bacteria in a more efficient manner. Despite the significant advances of antibiotic nanocarriers, many challenges like poor biocompatibility, premature drug release, suboptimal targeting to infection sites and short blood circulation time are still challenging. To achieve targeted drug delivery and enhance antibacterial activity, here we reported a kind of pH-responsive nanoparticles by simply self-assembly of an amphiphilic poly(ethylene glycol)-Schiff-vancomycin (PEG-Schiff-Van) prodrug and free Van in one drug delivery system. The acid-liable Schiff base furnished the PEG-Schiff-Van@Van with good storage stability in the neutral environment and susceptible disassembly in response to faintly acidic condition. Notably, on account of the combination of physical encapsulation and chemical conjugation of vancomycin, these nanocarriers with favorable biocompatibility and high drug loading capacity displayed a programmed drug release behavior, which was capable of rapidly reaching high drug concentration to effectively kill the bacteria at an early period and continuously exerting an bacteria-sensitive effect whenever needed over a long period. In addition, more Schiff-base moieties within the PEG-Schiff-Van@Van nanocarriers may also make great contributions on promoting the antimicrobial activity. Using this strategy, this system was designed to have programmable structural destabilization and sequential drug release due to changes in pH that were synonymous with bacterial infection sites, thereby presenting prominent antibacterial therapy both in vitro and in vivo. This work represents a synergistic strategy on offering important guidance to rational design of multifunctional antimicrobial vehicles, which would be a promising class of antimicrobial materials for potential clinical translation.
Lady of questions and answers (Isobel Barnett).
Journal: BMJ (1979)

In and Out of Medicine Lady of questions and answers Medicine has been much more use to her than she has been to medicine, says Isobel Barnett, and she still feels guilty that she may have taken a place from someone who would have continued as a doctor all his or her life.Born in Aberdeen, Lady Barnett was brought up in Glasgow where her father was an eminent neurologist, and she maintains that it was through nepotism that she was accepted into medical school there when she was 17. (At that time, she was one of 15 girls in a class of over 250.)She married (the best thing she ever did) while still a house
The Oestrogens
Authors: G. I. M. Swyer
Journal: BMJ (1959)

The oestrogens available for clinical use fall into three main groups-namely, natural, synthetic, and semi- synthetic.Natural Oestrogens.-Of these, oestradiol is the most potent and is administered in the form of esters (for example, benzoate or dipropionate) by intramuscular in- jection.The effect is relatively short-lived, and repeated injections-two or three times a week, or more oftenare needed for sustained effects.The therapeutic dose is about 1 mg.Oestradiol valerianate is a long-acting ester, a single intramuscular injection of 10 mg.lasting for 20 to 30 days.Oestradiol benzoate microcrystals can also be used as a long-acting preparation for intra- muscular injection.Relative Potencies of Some Oral Oestrogens Oestrogen
Effect of Remote Ischemic Conditioning in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis
Authors: Nehal Nasr Mahmoud, Fatma Mohamed Sayed, Manar Ahmed Kamal, Amal Suliman Alttaira, Sarah Makram Elsayed, Mais Hutham Sabri, Ahmed Alaa AbdelAzim, Fatma A. Monib, Sondos Hussien Osman, Massara Ben Ahmeida, Maisa Saleh Assiwi
Journal: Metabolism (2022)
Whooping-cough vaccine. Statement by Joint Committee on Vaccination and Immunization of the Central Health Services Council and the Scottish Health Service Planning Council.
Journal: BMJ (1975)

In 1974 it was recommended that pertussis vaccine should continue to be offered in a triple vaccine together with diphtheria and tetanus vaccines. Further data on the prevalence of whooping cough and the incidence of adverse reactions have shown no reason to change this policy; the hazard of whooping cough remains greater than that of immunization.
RATS IN RELATION TO PLAGUE
Authors: B. Skinner
Journal: BMJ (1905)

_ I__ B_ls427 the raw sterile ascitic fluid were added.At the end of a week at 370 C. acid reactions had appeared in the case of glucose and galactose, but in the case of saccharose and maltose the reaction of the medium was unchanged.All three colonies reqponded in the same way to these carbohydrate tests.6.A Gram negative Coccus from the Normal Urethra.-Thismicro-organism was isolated from mucus present in a sample of normal urine and was found to grow readily on ordinary egar at 370 C., and on ordinary gelatine at 200 C.When examined in the carbohydrate tests the coccus rapidly pro- ,duced an acid reaction in all four, namely, in glucose, galac- tose, maltose, and also in eaccharose.The Chief Characters of the Six Gram-negative Cocci.Carbobydrates.Production a ~~~~~of an Acid 3jO Growth Growth Reaction in Source.on ___Growth_on 0 liource.r-Son Napgar Gelatine A 2'o At 370 Iat 0 I;E-4 2a00C.WI .i 0 !Z I.N~~~-(M[ catarrhalis.)Nasal 23 65 Opaque Pcsitive _ _ _ _ .andpharyngeal secre- granular tion in 22 cases of the! Hertford outbreak' Sputum chronic bronchitis '!Nasal secretion Of 2 2 4 Opaque Negative + + + + Hertford cases in both granular of which B. diphtheriaet also present 3 Nasal secretion of 4 Clear, Negative + -+ - Hertford case in whichl smooth, at first.Coccus No.I also pre-l later positive sent becomes later yellowisb 4 (Meningococcus )Lumbar 3 9 Clear.Negative + + + puncture 2 specimens: smooth meninges post-mortem I specimen *; (Gooococcus.)Urethra] 3 No Negative + + -- pus growth unless blood added to medium 6 Mucus from normal ure-I 2 Opaque, Positive + + + + thlra 30somewhal granular It centre but imooth at edge CONCLUSION.It follows from these observations that while the virulence for mice and guinea-pigs of the various Gram-negative cocci examined appears to be of little.if any, value for differentiating them, the effect of these cocci upon glucose, galactose, maltose, and saccharose, respectively, is of much value for this purpose.Owing.to the special pathogenic significance of the meningococetS, gonococcus, and possibly also of M. catarrhalis and other individuals of the group, it is advis- able in future, when examining a Gram-negative coccus, to test it, amongst other things, in all the four carbohydrate media before considering that its identity has been estab- lished.If mistakes are to be avoided, this procedure would seem to be particularly desirable-I may even say necessarywhen examining nasal or pharyngeal secretion for the imeningococcus, or when examining discharge from the urino- genital tract, or other material, for the gonococcus.
The Association Between Antibiotic Use and Outcome Among Metastatic Melanoma Patients Receiving Immunotherapy
Authors: Florence Poizeau, Sandrine Kerbrat, Frédéric Balusson, Pierre Tattevin, Matthieu Revest, Vincent Cattoir, David Luque-Paz, Thierry Lesimple, Marc Pracht, Monica Dinulescu, David Russo, Emmanuel Oger, Alain Dupuy
Journal: JNCI Journal of the National Cancer Institute (2022)

Several observational studies have reported a decreased response to immune checkpoint inhibitors (ICI) following antibiotic use. ICI activity has been hypothesized to be impaired by antibiotic-induced gut dysbiosis.Patients with advanced melanoma receiving an anti-PD-1 antibody as a first-line therapy between 2015 and 2017 in France were selected using the French Health Insurance database. We compared overall survival and time-to-treatment discontinuation according to antibiotic exposure in the 3 months prior to the initiation of anti-PD-1 antibody. To disentangle a causal effect of antibiotics from a confounding bias, we balanced characteristics of patients exposed and nonexposed to antibiotics using an overlap weighting method based on a propensity score. We also evaluated a control cohort of patients with advanced melanoma receiving first-line targeted therapy, as there is no rationale for decreased efficacy of targeted therapy following antibiotic treatment.The anti-PD-1 antibody cohort comprised 2605 individuals. Antibiotic exposure in the 3 months prior to anti-PD-1 antibody initiation was not associated with shorter overall survival (weighted hazard ratio = 1.01, 95% confidence interval = 0.88 to 1.17) or time-to-treatment discontinuation (weighted hazard ratio = 1.00, 95% confidence interval = 0.89 to 1.11). Consistent results were observed when the time frame of antibiotics was narrowed to 1 month prior to anti-PD-1 initiation or when exposure was restricted to antibiotics leading to more profound gut dysbiosis. Similar results were observed in the targeted therapy cohort.In a large cohort of advanced melanoma patients, we showed that antibiotic use preceding anti-PD-1 antibody was not associated with worse outcome. Physicians should not delay immunotherapy for patients who have recently received antibiotics.
Polymersome-mediated cytosolic delivery of cyclic dinucleotide STING agonist enhances tumor immunotherapy
Authors: Huan Zheng, Beibei Guo, Xinyun Qiu, Yifeng Xia, Yan Qu, Liang Cheng, Fenghua Meng, Zhiyuan Zhong
Journal: Bioactive Materials (2022)
Dr. Eichberg.
Authors: Wm. H. Taylor
Journal: JAMA (1898)

Cincinnati, June 29, 1898. <h3>To the Editor:</h3> —Please correct statement of your Cincinnati correspondent, in last issue, that "Dr. Jos. Eichberg has resigned from Miami Medical College." He has resigned the office of Secretary, but retains his position of Professor of Practice. Dr. Olive P. Holt has been made Secretary of the College. Respectfully,
Seeking 'Indian-acceptable' ways to fight hypertension
Journal: JAMA (1985)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
LIFU-responsive nanomedicine enables acoustic droplet vaporization-induced apoptosis of macrophages for stabilizing vulnerable atherosclerotic plaques
Authors: Jingxin Hou, Jun Zhou, Meiqi Chang, Guangcheng Bao, Jie Xu, Man Ye, Yixin Zhong, Shuling Liu, Junrui Wang, Wei Zhang, Haitao Ran, Zhigang Wang, Yu Chen, Dajing Guo
Journal: Bioactive Materials (2022)

Due to the high risk of tearing and rupture, vulnerable atherosclerotic plaques would induce serious cardiovascular and cerebrovascular diseases. Despite the available clinical methods can evaluate the vulnerability of plaques and specifically treat vulnerable plaques before a cardiovascular event, but the efficiency is still low and undesirable. Herein, we rationally design and engineer the low-intensity focused ultrasound (LIFU)-responsive FPD@CD nanomedicine for the highly efficient treatment of vulnerable plaques by facilely loading phase transition agent perfluorohexane (PFH) into biocompatible PLGA-PEG-PLGA nanoparticles (PPP NPs) and then attaching dextran sulphate (DS) onto the surface of PPP NPs for targeting delivery. DS, as a typical macrophages-targeted molecule, can achieve the precise vaporization of NPs and subsequently controllable apoptosis of RAW 264.7 macrophages as induced by acoustic droplet vaporization (ADV) effect. In addition, the introduction of DiR and Fe3O4 endows nanomedicine with near-infrared fluorescence (NIRF) and magnetic resonance (MR) imaging capabilities. The engineered FPD@CD nanomedicine that uses macrophages as therapeutic targets achieve the conspicuous therapeutic effect of shrinking vulnerable plaques based on in vivo and in vitro evaluation outcomes. A reduction of 49.4% of vascular stenosis degree in gross pathology specimens were achieved throughout the treatment period. This specific, efficient and biosafe treatment modality potentiates the biomedical application in patients with cardiovascular and cerebrovascular diseases based on the relief of the plaque rupture concerns.